Join us   Log in   pharmaspire@isfcp.org  


PHARMASPIRE - Volume 13, Issue 4 , October - December, 2021

Pages: 182-193
Print Article   Download XML  Download PDF

Design, synthesis, and characterization of new thiazolidinedione derivatives as potent α-glucosidase inhibitors

Author: Sobhi Gaba, Gurpreet Singh, Vikramdeep Monga

Category: Pharmaceutics

Abstract:

In an effort to find new antidiabetic agents, we carried out the design and synthesis of new thiazolidinedione derivatives and evaluated them as α-glucosidase inhibitors. All the synthesized derivatives were evaluated for α-glucosidase inhibitory activity. All the derivatives showed good inhibitory potential against α-glucosidase with IC50 values ranging between 35.74 ± 0.134 and 12.29 ± 1.86 μg/mL. Among all the synthesized derivatives, 12d emerged to be the most potential inhibitor of α-glucosidase bearing IC50 value of 12.29 ± 1.86 μg/mL. Owing to the results, it can be concluded that the lead identified in the present study can be further explored for the design of potent α-glucosidase inhibitors as antidiabetic agents.

Keywords: Thiazolidinedione, ?-glucosidase inhibitors, antidiabetic agents, synthesis, in vitro studies

References:

  1. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016;12:357-70.
  2. Reusch JE, Manson JE. Management of Type 2 diabetes in 2017: Getting to goal. JAMA 2017;317:1015-6.
  3. Martin BC, Warram JH, Krolewski AS, Soeldner J, Kahn C, Bergman R. Role of glucose and insulin resistance in development of Type 2 diabetes mellitus: Results of a 25-year follow-up study. Lancet 1992;340:925-9.
  4. Gollapalli M, Taha M, Ullah H, Nawaz M, AlMuqarrabun LMR, Rahim F, et al. Synthesis of bis-indolylmethane sulfonohydrazides derivatives as potent α-glucosidase inhibitors. Bioorg Chem 2018;80:112-20.
  5. Chaudhry F, Choudhry S, Huma R, Ashraf M, Al-Rashida M, Munir R, et al. Hetarylcoumarins: Synthesis and biological evaluation as potent α-glucosidase inhibitors. Bioorg Chem 2017;73:1-9.
  6. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for Type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD003639.
  7. Akmal M, Wadhwa R. Alpha Glucosidase Inhibitors. Treasure Island, FL: StatPearls; 2021.
  8. Smith DL, Orlandella RM, Allison DB, Norian LA. Diabetes medications as potential calorie restriction mimetics a focus on the alpha-glucosidase inhibitor acarbose. Geroscience 2021;43:1123-33.
  9. Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new α-glucosidase inhibitor. Expert Opin Pharmacother 1999;1:149-56.
  10. Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An alpha glucosidase inhibitor. J Clin Diagn Res 2013;7:3023.
  11. Tahlan S, Verma PK. Biological potential of thiazolidinedione derivatives of synthetic origin. Chem Cent J 2017;11:1-29.
  12. Hussain F, Khan Z, Jan MS, Ahmad S, Ahmad A, Rashid U, et al. Synthesis, in-vitro α-glucosidase inhibition, antioxidant, in-vivo antidiabetic and molecular docking studies of pyrrolidine-2, 5-dione and thiazolidine-2, 4-dione derivatives. Bioorg Chem 2019;91:103128.
  13. Chinthala Y, Domatti AK, Sarfaraz A, Singh SP, Arigari NK, Gupta N, et al. Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring. Eur J Med Chem 2013;70:308- 14.
  14. Taha M, Ismail NH, Imran S, Mohamad MH, Wadood A, Rahim F, et al. Synthesis, α-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl7-methylbenzimidazoles. Bioorg Chem 2016;65:100-9.
  15. Sridhar S, Bhurta D, Kantiwal D, George G, Monga V, Paul AT. Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors. Bioorg Med Chem Lett 2017;27:3749-54.